{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matching+placebo+injections&page=5", "query": { "intervention": "matching placebo injections", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 940, "total_pages": 94, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matching+placebo+injections&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matching+placebo+injections&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T23:56:22.369Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05271409", "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)" ], "interventions": [ { "name": "Satralizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 132, "start_date": "2022-08-30", "completion_date": "2028-05-20", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05271409" }, { "nct_id": "NCT05526716", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumonia, Pneumococcal" ], "interventions": [ { "name": "V116", "type": "BIOLOGICAL" }, { "name": "QIV", "type": "BIOLOGICAL" }, { "name": "Matching Placebo for V116", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1080, "start_date": "2022-09-23", "completion_date": "2023-06-21", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 56, "location_summary": "Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05526716" }, { "nct_id": "NCT01356160", "title": "GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin tablet", "type": "DRUG" }, { "name": "GS-9451 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 351, "start_date": "2011-07", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 21, "location_summary": "Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356160" }, { "nct_id": "NCT01828086", "title": "Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Plaque-type Psoriasis" ], "interventions": [ { "name": "CJM112", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 95, "start_date": "2013-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 18, "location_summary": "Anniston, Alabama • Anaheim, California • Encino, California + 14 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01828086" }, { "nct_id": "NCT01425970", "title": "Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "INX-08189", "type": "DRUG" }, { "name": "Placebo matching with INX-08189", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 210, "start_date": "2012-05", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 6, "location_summary": "Anaheim, California • La Jolla, California • San Francisco, California + 3 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01425970" }, { "nct_id": "NCT01060254", "title": "A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystitis, Interstitial", "Urologic Diseases", "Urinary Bladder Diseases", "Cystitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "JNJ-42160443", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 31, "start_date": "2010-04-06", "completion_date": "2011-06-24", "has_results": false, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Glendora, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Glendora", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01060254" }, { "nct_id": "NCT05194124", "title": "Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bardet-Biedl Syndrome", "POMC Deficiency" ], "interventions": [ { "name": "Setmelanotide 2 mg", "type": "DRUG" }, { "name": "Setmelanotide 2.5 mg", "type": "DRUG" }, { "name": "Setmelanotide 3 mg", "type": "DRUG" }, { "name": "Setmelanotide 20 mg", "type": "DRUG" }, { "name": "Setmelanotide 25 mg", "type": "DRUG" }, { "name": "Setmelanotide 30 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 19, "start_date": "2021-12-21", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Marshfield, Wisconsin", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Marshfield", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05194124" }, { "nct_id": "NCT01984424", "title": "Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo to Atorvastatin", "type": "DRUG" }, { "name": "Placebo to Ezetimibe", "type": "OTHER" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo to Evolocumab", "type": "OTHER" }, { "name": "Evolocumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 511, "start_date": "2013-12-10", "completion_date": "2017-11-21", "has_results": true, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 18, "location_summary": "Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Pedro", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01984424" }, { "nct_id": "NCT02898454", "title": "Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)" ], "interventions": [ { "name": "Dupilumab SAR231893 (REGN668)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate nasal spray", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2016-11-28", "completion_date": "2018-11-16", "has_results": true, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02898454" }, { "nct_id": "NCT05774756", "title": "A Trial of Setmelanotide in Acquired Hypothalamic Obesity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypothalamic Obesity" ], "interventions": [ { "name": "Setmelanotide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 143, "start_date": "2023-04-26", "completion_date": "2027-04-16", "has_results": true, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-12T23:56:22.369Z", "location_count": 16, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05774756" } ] }